Form 4: Repare Therapeutics Director Sells Shares in Acquisition

Repare Therapeutics Director Thomas Civik sold 7,500 shares as part of the company's acquisition by Xeno Acquisition Corp. for $2.20 cash and a CVR.

Summary

• Thomas Civik, a Director of Repare Therapeutics Inc. (RPTX), reported the disposal of 7,500 common shares.
• The transaction occurred on January 28, 2026.
• This disposal was made pursuant to an Arrangement Agreement dated November 14, 2025, between Repare Therapeutics Inc., XenoTherapeutics, Inc. (Parent), Xeno Acquisition Corp. (Purchaser), and XOMA Royalty Corporation (XRC).
• Under the agreement, the Purchaser acquired all issued and outstanding common shares of Repare Therapeutics Inc. for $2.20 in cash per share, plus one non-transferable contingent value right (CVR) per share.

Sentiment

Score: 5

Explanation: The filing is a factual report of an insider transaction related to a previously announced acquisition, thus presenting a neutral sentiment regarding new company performance or strategic direction.

Future Outlook

The acquisition by Xeno Acquisition Corp. implies the cessation of Repare Therapeutics Inc. as an independent publicly traded entity. The contingent value rights (CVRs) represent a potential future payment to former shareholders, contingent upon specific future events or milestones.

Industry Context

This transaction reflects a common trend in the biotechnology and pharmaceutical sectors where smaller, innovative companies are acquired by larger entities, often involving a combination of upfront cash and contingent value rights to account for future potential value.

Stakeholder Impact

• Shareholders of Repare Therapeutics Inc. received $2.20 in cash and one non-transferable CVR for each common share as part of the acquisition.

Next Steps

• Realization of value from the contingent value rights (CVRs) will depend on the achievement of specific future conditions or milestones as outlined in the Arrangement Agreement.

Key Dates

Keywords

Repare Therapeutics, RPTX, Thomas Civik, Insider Transaction, Acquisition, XenoTherapeutics, Contingent Value Right, CVR, Form 4